Clinical and laboratory assessment of antimalarial drug efficacy in Lao PDR: an open, randomised comparison of artesunate plus mefloquine versus dihydroartemisinin-piperaquine (Artekin) for the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic

Submission date 22/07/2005	<b>Recruitment status</b> No longer recruiting	<ul><li>☐ Prospectively registered</li><li>☐ Protocol</li></ul>
Registration date 22/07/2005	Overall study status Completed	<ul><li>Statistical analysis plan</li><li>[X] Results</li></ul>
<b>Last Edited</b> 11/03/2013	Condition category Infections and Infestations	Individual participant data

## Plain English summary of protocol

Not provided at time of registration

# **Contact information**

## Type(s)

Scientific

#### Contact name

Dr Mayfong Mayxay

#### Contact details

Mahosot Hospital
Microbiology Laboratory
Mahosot Road
Vientiane
Lao People's Democratic Republic
PO Box 5
+856 (0)21 250752
Mayfong@tropmedres.ac

## Additional identifiers

#### **EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

065146

# Study information

Scientific Title

#### **Study objectives**

An open, randomised comparison of artesunate plus mefloquine versus dihydroartemisininpiperaquine (Artekin) for the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

### Participant information sheet

## Health condition(s) or problem(s) studied

Uncomplicated falciparum malaria

#### **Interventions**

- 1. Oral Artesunate-Mefloquine (AM)
- 2. Dihydroartemisinin-piperaquine (Artekin)

### Intervention Type

Drug

#### Phase

**Not Specified** 

### Drug/device/biological/vaccine name(s)

Artesunate, mefloquine, and dihydroartemisinin-piperaquine (Artekin)

#### Primary outcome measure

Parasitological and clinical responses to treatment.

#### Secondary outcome measures

- 1. Parasite and fever clearance times
- 2. Gametocytaemia
- 3. Changes in haematocrit following antimalarial treatment

#### Overall study start date

20/05/2004

#### Completion date

20/09/2004

# **Eligibility**

#### Key inclusion criteria

- 1. Patients or their quardians gave fully informed written consent
- 2. Had a density of asexual P. falciparum of 1000 to 200,000 per microlitre of blood
- 3. Were aged more than one year
- 4. Had an axillary temperature of more than 37.5°C or history of fever in the previous three days
- 5. Were likely to stay in the hospital until parasite clearance and complete the 42-day follow up period

### Participant type(s)

Patient

#### Age group

**Not Specified** 

#### Sex

Both

### Target number of participants

220

#### Key exclusion criteria

- 1. Pregnant or lactating women
- 2. Patients who took a full course of any antimalarials in the previous three days
- 3. Patients with signs of severe malaria
- 4. Those with history of allergy or contraindication to the study drugs

# Date of first enrolment

20/05/2004

#### Date of final enrolment

20/09/2004

## Locations

#### Countries of recruitment

Lao People's Democratic Republic

# Study participating centre

Mahosot Hospital

Vientiane Lao People's Democratic Republic PO Box 5

# Sponsor information

#### Organisation

University of Oxford (UK)

## Sponsor details

University Offices Wellington Square Oxford England United Kingdom OX1 2JD

#### Sponsor type

University/education

#### Website

http://www.ox.ac.uk

#### **ROR**

https://ror.org/052gg0110

# Funder(s)

#### Funder type

Research organisation

#### Funder Name

The Western Pacific Regional Office of the World Health Organisation (Philippines)

#### Funder Name

The Wellcome Trust (UK) (grant ref: 065146)

## **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2006		Yes	No